Ferrero, S
Ladetto, M
Drandi, D
Cavallo, F
Genuardi, E
Urbano, M
Caltagirone, S
Grasso, M
Rossini, F
Guglielmelli, T
Cangialosi, C
Liberati, A M
Callea, V
Carovita, T
Crippa, C
De Rosa, L
Pisani, F
Falcone, A P
Pregno, P
Oliva, S
Terragna, C
Musto, P
Passera, R
Boccadoro, M
Palumbo, A
Article History
Received: 24 April 2014
Revised: 17 June 2014
Accepted: 8 July 2014
First Online: 16 July 2014
Competing interests
: ML—Celgene, Jannsen Cilag, Mundipharma, Roche and Amgen: research funding, speaker's bureau. FC—Celgene and Jannsen Cilag: consultancy membership on an entity's Board of Directors and advisory committees. TC—Celgene: honoraria, research funding, Jannsen Cilag: honoraria. TG—Celgene: research funding. PM—Celgene: honoraria, research funding. MB—Celgene: consultancy, membership on an entity’s Board of Directors or advisory committees, research funding; Jannsen Cilag: consultancy, membership on an entity’s Board of Directors or advisory committees, research funding. AP—Bristol–Myers Squibb, Celgene, Janssen Pharmaceuticals, Onyx and Amgen: consultancy, honoraria. The remaining authors declare no conflict of interest.